# Sue Haupt

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 68 papers | 3,204 citations | 172207 29 h-index | 161609 54 g-index |
| 127 all docs | 127 docs citations | 127 times ranked | 5980 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity. Frontiers in Genetics, 2021, 12, 632719. | 1.1 | 10 |
| 2 | Sex disparities matter in cancer development and therapy. Nature Reviews Cancer, 2021, 21, 393-407. | 12.8 | 136 |
| 3 | SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response thanTP53Mutation Status. Molecular Cancer Therapeutics, 2021, 20, 1858-1867. | 1.9 | 24 |
| 4 | MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Research, 2020, 22, 87. | 2.2 | 37 |
| 5 | Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. BMC Urology, 2020, 20, 171. | 0.6 | 7 |
| 6 | P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. International Journal of Molecular Sciences, 2020, 21, 3452. | 1.8 | 56 |
| 7 | TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. Cancers, 2020, 12, 1535. | 1.7 | 30 |
| 8 | High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792. | | 45 |
| 9 | Predicting radiation-induced immune trafficking and activation in localized prostate cancer.. Journal of Clinical Oncology, 2020, 38, 340-340. | 0.8 | 0 |
| 10 | Cannibalism in Breast Cancer: The Dangers of Overeating. Trends in Cancer, 2019, 5, 761-762. | 3.8 | 4 |
| 11 | Regulation of PRMT5â€“MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17990-18000. | 3.3 | 81 |
| 12 | Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Letters, 2019, 461, 21-30. | 3.2 | 18 |
| 13 | E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers. Carcinogenesis, 2019, 40, 707-714. | 1.3 | 15 |
| 14 | A quantitative model to predict pathogenicity of missense variants in the TP53 gene. Human Mutation, 2019, 40, 788-800. | 1.1 | 21 |
| 15 | The long and the short of it: the MDM4 tail so far. Journal of Molecular Cell Biology, 2019, 11, 231-244. | 1.5 | 52 |
| 16 | Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects. Cell Reports, 2019, 27, 442-454.e5. | 2.9 | 37 |
| 17 | E6AP Promotes a Metastatic Phenotype in Prostate Cancer. IScience, 2019, 22, 1-15. | 1.9 | 11 |
| 18 | Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nature Communications, 2019, 10, 5385. | 5.8 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.. Journal of Clinical Oncology, 2019, 37, 22-22. | 0.8 | 1 |
| 20 | Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells. Molecular and Cellular Proteomics, 2018, 17, 1170-1183. | 2.5 | 13 |
| 21 | Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. Redox Biology, 2018, 14, 100-115. | 3.9 | 261 |
| 22 | PO-126 Exploration of novel regulators of mutant P53. ESMO Open, 2018, 3, A70. | 2.0 | 0 |
| 23 | Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice. Blood Advances, 2018, 2, 347-360. | 2.5 | 16 |
| 24 | <scp>MDM4</scp> is a rational target for treating breast cancers with mutant p53. Journal of Pathology, 2017, 241, 661-670. | 2.1 | 32 |
| 25 | Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in nonâ€“small cell lung cancer. Science Signaling, 2017, 10, . | 1.6 | 24 |
| 26 | Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer. Molecular and Cellular Oncology, 2017, 4, e1299273. | 0.3 | 6 |
| 27 | Inhibiting the system xCâ^'/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nature Communications, 2017, 8, 14844. | 5.8 | 229 |
| 28 | The role of MDM2 and MDM4 in breast cancer development and prevention. Journal of Molecular Cell Biology, 2017, 9, 53-61. | 1.5 | 56 |
| 29 | P53 at the start of the 21st century: lessons from elephants. F1000Research, 2017, 6, 2041. | 0.8 | 15 |
| 30 | E6AP promotes prostate cancer by reducing p27 expression. Oncotarget, 2017, 8, 42939-42948. | 0.8 | 25 |
| 31 | New insights on the regulation of INK4/ARF locus expression. Oncotarget, 2017, 8, 106147-106148. | 0.8 | 2 |
| 32 | Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology, 2016, 6, 7. | 1.3 | 266 |
| 33 | Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways. Frontiers in Oncology, 2016, 6, 12. | 1.3 | 49 |
| 34 | The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Research, 2016, 76, 4236-4248. | 0.4 | 45 |
| 35 | Abstract 4357: Harnessing system xCT- to target mutant p53 cancer cells. , 2016, , . | | 0 |
| 36 | Regulation of Mutant p53 Protein Expression. Frontiers in Oncology, 2015, 5, 284. | 1.3 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut, 2015, 64, 1506-1516. | 6.1 | 84 |
| 38 | Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nature Communications, 2015, 6, 7389. | 5.8 | 104 |
| 39 | p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress. Frontiers in Oncology, 2015, 5, 57. | 1.3 | 12 |
| 40 | Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death and Disease, 2015, 6, e1821-e1821. | 2.7 | 37 |
| 41 | Role of p53 in the progression of gastric cancer. Oncotarget, 2014, 5, 12016-12026. | 0.8 | 64 |
| 42 | The p53-Mdm2 Loop: A Critical Juncture of Stress Response. Sub-Cellular Biochemistry, 2014, 85, 161-186. | 1.0 | 31 |
| 43 | PML tumour suppression and beyond: Therapeutic implications. FEBS Letters, 2014, 588, 2653-2662. | 1.3 | 18 |
| 44 | Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. Annals of Oncology, 2014, 25, 2392-2397. | 0.6 | 22 |
| 45 | The E6AP E3 ubiquitin ligase regulates the cellular response to oxidative stress. Oncogene, 2013, 32, 3510-3519. | 2.6 | 23 |
| 46 | Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain. Cell Death and Differentiation, 2013, 20, 852-854. | 5.0 | 10 |
| 47 | c-Abl Phosphorylates E6AP and Regulates Its E3 Ubiquitin Ligase Activity. Biochemistry, 2013, 52, 3119-3129. | 1.2 | 23 |
| 48 | Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle, 2013, 12, 1722-1731. | 1.3 | 25 |
| 49 | New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers. Frontiers in Oncology, 2013, 3, 124. | 1.3 | 14 |
| 50 | Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruption. Cell Cycle, 2012, 11, 217-218. | 1.3 | 6 |
| 51 | Restoring PML tumor suppression to combat cancer. Cell Cycle, 2012, 11, 3705-3706. | 1.3 | 3 |
| 52 | E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood, 2012, 120, 822-832. | 0.6 | 50 |
| 53 | MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine, 2012, 18, 1239-1247. | 15.2 | 266 |
| 54 | Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. Journal of Drug Targeting, 2011, 19, 859-873. | 2.1 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53. Cancer Research, 2009, 69, 4818-4826. | 0.4 | 76 |
| 56 | Tumour suppression by p53: the importance of apoptosis and cellular senescence. Journal of Pathology, 2009, 219, 3-15. | 2.1 | 156 |
| 57 | E6AP promotes the degradation of the PML tumor suppressor. Cell Death and Differentiation, 2009, 16, 1156-1166. | 5.0 | 88 |
| 58 | PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene, 2008, 27, 3653-3661. | 2.6 | 66 |
| 59 | p53 controls hPar1 function and expression. Oncogene, 2008, 27, 6866-6874. | 2.6 | 19 |
| 60 | T cell survival and function requires the c-Abl tyrosine kinase. Cell Cycle, 2008, 7, 3847-3857. | 1.3 | 24 |
| 61 | Importance of p53 for cancer onset and therapy. Anti-Cancer Drugs, 2006, 17, 725-732. | 0.7 | 36 |
| 62 | Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species. Anti-Cancer Drugs, 2006, 17, 609-619. | 0.7 | 6 |
| 63 | Clues from worms: a Slug at Puma promotes the survival of blood progenitors. Cell Death and Differentiation, 2006, 13, 913-915. | 5.0 | 25 |
| 64 | Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. European Journal of Pharmaceutical Sciences, 2006, 28, 204-211. | 1.9 | 44 |
| 65 | C-Abl as a modulator of p53. Biochemical and Biophysical Research Communications, 2005, 331, 737-749. | 1.0 | 54 |
| 66 | Mdm2 in growth signaling and cancer. Growth Factors, 2005, 23, 183-192. | 0.5 | 52 |
| 67 | New exciting possibilities for the development of precision medicine therapies to restore the expression of the INK4/ARF locus. Annals of Research Hospitals, 0, 1, 1-1. | 0.0 | 0 |
| 68 | Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer. Oncology Abstracts, 0, , . | 0.0 | 0 |